SCHEMBL10154032

SCHEMBL10154032

Cc1cc(C)cc(-n2c(=O)c3cc4c(=O)n(C)c(=O)c4cc3c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
CCR6 P51684 1/20 0.41
COMT P21964 2/20 0.40
MAPT P10636 3/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.35
BRD9 Q9H8M2 1/20 0.35
BRD7 Q9NPI1 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12163402 0.84 TPMT (0.47) MAPTKDM4EALDH1A1NPSR1MEN1
SCHEMBL862493 0.82 CA12 (0.49) HSP90AA1MAPTCA12CA1CA2
SCHEMBL12780772 0.82 ALDH1A1 (0.52) HSP90AA1KDM4EALDH1A1LMNAMEN1
SCHEMBL760106 0.78 CA12 (0.45) HSP90AA1MAPTCA12CA1CA2
SCHEMBL862264 0.78 ALDH1A1 (0.46) MAPTKDM4EALDH1A1LMNANPSR1
SCHEMBL862492 0.76 MAPK1 (0.61) MAPTCA12CA1CA2CA9
SCHEMBL17676354 0.76 MEN1 (0.52) MAPTCA12CA1CA2CA9
SCHEMBL17789200 0.75 ALDH1A1 (0.44) MAPTKDM4EALDH1A1LMNANPSR1
SCHEMBL758750 0.74 LMNA (0.44) MAPTCA12CA1CA2CA9
SCHEMBL9979462 0.74 CA12 (0.41) HSP90AA1MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240069257-A1 CHOLESTERIC LIQUID CRYSTAL LAYER, METHOD OF FORMING CHOLESTERIC LIQUID CRYSTAL LAYER, LAMINATE, LIGHT GUIDE ELEMENT, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2024-02-29 US disclosed
US-20120041203-A1 METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-16 US disclosed
US-7989037-B2 A layer of discotic liquid-crystal and an anisotropic fluoropolymer of acrylic esters, e.g., 4-((4-nitrilophenoxy)butyl acrylate /2-(perfluorhexyl)ethyl acrylate copolymer; providing stability/optical compensation; no defects from optical fluctuation or alignment failure; controlling the tilt angle FUJIFILM CORPORATION (JP) 2011-08-02 US disclosed
US-20080090027-A1 Composition, retardation plate, and liquid-crystal display device FUJIFILM CORPORATION (JP) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041203-A1 METAL COMPLEX HAVING AROMATIC RING LIGAND CONTAINING NITROGEN ATOM MICA, CD4, CLTC HSP90AA1 183/4885CCR6 348/4885COMT 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.